Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a Study of IP-QSV Shigella Vaccine in Healthy Adults, Children, and Infants
NCT07666750Phase 2Not yet recruiting
- Sponsor
- International Vaccine Institute
- Start
- Jul 2026
- Primary completion
- Aug 2027
01
Overview
A Phase 2 trial of IP-QSV in Shigella infection, sponsored by International Vaccine Institute. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
IP-QSV
03
Conditions
Shigella infection
Beyond the preview
Go deeper on NCT07666750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07666750.